ZEULIDE DEPOT™ IS NOW COVERED BY THE ONTARIO DRUG BENEFIT (ODB) PROGRAM FOR PATIENTS LIVING WITH PROSTATE CANCER.
Toronto, Ontario, May 29, 2020 — Verity Pharmaceuticals Inc. is pleased to announce that as of May 29, 2020, Zeulide Depot™ (Leuprolide acetate for depot suspension), a hormone therapy for the palliative treatment of prostate cancer, has been added as a General Benefit through the Ontario Drug Benefit (ODB) Program. Zeulide Depot™ is a Luteinizing […]Learn More
VERITY PHARMACEUTICALS ACQUIRES PENDOPHARM’S RIGHTS TO COMMERCIALIZE ZEULIDE DEPOT™ FOR THE CANADIAN ONCOLOGY COMMUNITY.
Toronto, Ontario, June 27, 2019 — Verity Pharmaceuticals Inc. is pleased to announce that it has entered into an agreement with Pendopharm, a division of Pharmascience Inc., that will see Verity market and sell Zeulide Depot™ (Leuprolide acetate for depot suspension) to the Canadian healthcare community. Under the terms of the agreement, Pendopharm has divested […]Learn More
IVOZFO™ (fosfomycin for injection), a novel ‘first in class’ IV antibiotic approved for use in Canada. IVOZFO provides a new option for hard to treat infections, including multi-drug resistant superbugs.
Mississauga, Ontario, May 1, 2019 — Verity Pharmaceuticals announced today that, following a priority review, Health Canada has given a Notice of Compliance to their new antibiotic IVOZFO™ (fosfomycin for injection), for use in the Canadian healthcare community. IVOZFO has a chemical structure unrelated to other known intravenous antibiotics and is the first of its […]Learn More
VERITY PHARMACEUTICALS COMPLETES NEW DRUG SUBMISSION TO HEALTH CANADA FOR BCG BLADDER CANCER TREATMENT
Toronto, Ontario, November 1, 2018 — Verity Pharmaceuticals Inc. is pleased to announce submission of the New Drug Submission (NDS) to Health Canada for review and approval of VERITY-ONCO-BCG (Bacillus Calmette–Guérin) as an antineoplastic agent for bladder cancer instillation. The drug will be marketed in Canada through an exclusive licensing agreement with Serum Institute of […]Learn More
VERITY ANNOUNCES A LICENSING AGREEMENT FOR MITOMYCIN WITH VYGORIS, UK.
Toronto, Ontario, November 1, 2018 — Verity Pharmaceuticals Inc. is pleased to announce an exclusive Canadian licensing and supply agreement with Vygoris Ltd., London, UK, for the supply of Mitomycin to the Canadian pharmaceutical market. Under the terms of the exclusive agreement, Vygoris will supply the finished product and Verity will market and distribute. Mitomycin […]Learn More
VERITY PHARMACEUTICALS AND THE CANADIAN SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC. PARTNER TO PROVIDE PHENAZO® TO CANADIAN PHYSICIANS AND THEIR PATIENTS.
Toronto, Ontario, October 3, 2018 — Verity Pharmaceuticals Inc., a specialty pharmaceutical company, is pleased to announce an exclusive promotion agreement with the Canadian subsidiary of Bausch Health Companies Inc. for Phenazo®(phenazopyridine hydrochloride tablets) in 100mg and 200mg strengths. Under the terms of the agreement, the Canadian subsidiary of Bausch Health Companies Inc. will provide […]Learn More
Health Canada grants Intravenous Fosfomycin priority review status
Toronto, Ontario, July 16, 2018 – Following a pre-NDS meeting and subsequent application to fast track the review process, Intravenous Fosfomycin has been granted priority review status by Health Canada. Under priority review status the NDS (new drug submission) is deemed to meet an unmet medical need in Canada. Moreover, the NDS will be reviewed […]Learn More
Recent Publication: Intravenous Fosfomycin potential in Canada & it’s role with MDR pathogens
Toronto, Ontario, July 11, 2018 – A new clinical publication, Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada, has recently been published in the Canadian Journal of Infectious Diseases and Medical Microbiology.Learn More
Phenazopyridine Hydrochloride Tablets to return to Canadian market. Verity and Bi-Coastal Pharma International strike deal.
Toronto, Ontario, March 7, 2018 — Verity Pharmaceuticals Inc. is pleased to announce a manufacturing and supply agreement with Bi-Coastal Pharma International of Shrewsbury, New Jersey for the production of Phenazopyridine Hydrochloride Tablets in 100mg and 200mg strengths.Learn More
Verity announces licensing agreement with InfectoPharm to bring novel anti-infective to Canada
Toronto, Ontario, March 21, 2018 — Verity Pharmaceuticals Inc. is pleased to announce an exclusive Canadian licensing agreement with InfectoPharm Arzneimittel und Consilium GmbH, for the introduction of Intravenous Fosfomycin for the Canadian hospital market.Learn More
VERITY PHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF ALLAN SILBER TO THE BOARD OF DIRECTORS
Toronto, Canada, December 18, 2017 – Verity Pharmaceuticals Inc., (“Verity” or the “Company”) a specialty pharmaceutical company announced today the appointment of Mr. Allan Silber to the Board of Directors.Learn More
Verity Pharmaceuticals Appoints Scientific Advisory Board
Toronto, Canada, September 4, 2016 – Verity Pharmaceuticals Inc., (“Verity” or the “Company”) a specialty pharmaceutical company announced today the election of Drs. Jack Barkin, Neil Fleshner, Sender Herschorn, Robert Devenyi and David Dunne to its Scientific Advisory Board (“SAB”)Learn More
Appointment of Mr. R. Rieder As Chairman
Toronto, Canada, July 5, 2016 – Verity Pharmaceuticals Inc., (“Verity” or the “Company”) a specialty pharmaceutical company announced today the appointment of Mr. Robert Rieder as the Chairman of the Board.Learn More